Janux Therapeutics (JANX) Income towards Parent Company: 2020-2025
Historic Income towards Parent Company for Janux Therapeutics (JANX) over the last 6 years, with Sep 2025 value amounting to -$24.3 million.
- Janux Therapeutics' Income towards Parent Company rose 13.35% to -$24.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$101.9 million, marking a year-over-year decrease of 68.32%. This contributed to the annual value of -$69.0 million for FY2024, which is 18.36% down from last year.
- Latest data reveals that Janux Therapeutics reported Income towards Parent Company of -$24.3 million as of Q3 2025, which was up 28.19% from -$33.9 million recorded in Q2 2025.
- Janux Therapeutics' 5-year Income towards Parent Company high stood at -$2.3 million for Q1 2021, and its period low was -$33.9 million during Q2 2025.
- Its 3-year average for Income towards Parent Company is -$19.0 million, with a median of -$17.5 million in 2023.
- As far as peak fluctuations go, Janux Therapeutics' Income towards Parent Company plummeted by 757.17% in 2021, and later surged by 65.96% in 2024.
- Quarterly analysis of 5 years shows Janux Therapeutics' Income towards Parent Company stood at -$13.4 million in 2021, then declined by 19.75% to -$16.1 million in 2022, then increased by 26.81% to -$11.8 million in 2023, then slumped by 71.93% to -$20.2 million in 2024, then climbed by 13.35% to -$24.3 million in 2025.
- Its Income towards Parent Company stands at -$24.3 million for Q3 2025, versus -$33.9 million for Q2 2025 and -$23.5 million for Q1 2025.